Triple-drug combo could prove key weapon in fight against cancer
Combining three existing drugs – a commonly-used anti-epileptic, a contraceptive steroid and a cholesterol-lowering agent – could form an effective and non-toxic treatment for a range of aggressive…
Artificial Intelligence project aims to improve diversity and equality in AI systems
A new project has been launched across BHP members, aiming to address racial and ethical health inequalities using artificial intelligence (AI).
STANDING Together, being led by BHP founding member…
Birmingham leads the way in delivery of a new advanced therapy in uveal melanoma
BHP founder-member University Hospitals Birmingham is the first site in the UK to treat a uveal melanoma patient with the new therapy Tebentafusp outside a clinical trial. Uveal melanoma is a rare …
Genetic diagnosis leads the way in childhood eye cancer treatment
Experts from BHP member Birmingham Women’s and Children’s NHS Foundation Trust have transformed the treatment of children’s eye cancer with pioneering new research.
Dr Trevor Cole and Dr Amy Ger…
SPIRIT-PRO extension: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials
Patient Reported Outcomes (PROs) can provide valuable evidence on the impact of disease and treatment on patients’ symptoms, function and quality of life. High-quality PRO data from trials can info…
Scientists discover new pathway that prevents bowel cancer treatment from working
Leading scientists at BHP founder-member the University of Birmingham have discovered a previously unknown pathway that prevents specific drugs from working in patients with bowel cancer.
The rese…